PUT/VERTEX PHARMACEUTICALS/500/0.1/20.06.25 | Real-time BOERSE MUENCHEN 15:27:22 03/07/2024 BST | ||
| 5.08 EUR | -2.50% |
|
| Current month | +2.36% | ||
| 1 month | -19.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 5.08 | -2.50% |
| 02/07/24 | 5.21 | -0.95% |
| 01/07/24 | 5.26 | +3.34% |
| 28/06/24 | 5.09 | -1.55% |
| 27/06/24 | 5.17 | +0.19% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 03:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG3KYX |
| ISIN | DE000GG3KYX0 |
| Date issued | 06/02/2024 |
| Strike | 500 $ |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 8.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.53 € |
|---|---|
| Lowest since issue | 4.78 € |
| Spread | 0.2 € |
| Spread % | 3.70% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
